Document:

Exhibit
10.23

 

* Confidential Treatment Requested by Celera Corporation*

HIGHLY
CONFIDENTIAL

EXECUTION
VERSION

 

REAL-TIME INSTRUMENT PATENT LICENSE AGREEMENT

 

This REAL-TIME INSTRUMENT
PATENT LICENSE AGREEMENT (the “Agreement”) is entered into and made effective
as of the 25th of April, 2006 (the “Effective Date”)
by and among BECKMAN COULTER, INC., a Delaware corporation with its principal
offices located at 4300 North Harbor Boulevard, Fullerton, California 92835
(the “Licensee”), and APPLERA
CORPORATION, a Delaware Corporation, through its APPLIED BIOSYSTEMS group
located at 850 Lincoln Centre Drive, Foster City, California 94404, and its
CELERA GENOMICS group, located at 45 West Gude Drive, Rockville, Maryland 20850
(“Licensor”). Each of the parties to this
Agreement shall be referred to individually as a “Party” and collectively as the “Parties”.

 

WHEREAS, Licensee initiated a civil action in
the United States District Court for the Central District of California against
Applera Corporation on July 2, 2002, entitled Beckman Coulter, Inc.
v. Applera Corporation, SA CV 02-624 MRP (AN) (the “Patent Lawsuit”), in which
Licensee alleged infringement of certain patents owned by Licensee;

 

WHEREAS, Applera Corporation (“Applera”)
initiated a civil action in the Superior Court of California for the County of
San Francisco against Licensee on February 7, 2005, entitled Applera
Corporation v. Beckman Coulter, Inc., Case No. 05-438449
(collectively with the Patent Lawsuit, the “Lawsuits”) in which Applera alleged
that, contrary to Licensee’s obligations under a November 6, 1996
sublicense agreement between The Perkin-Elmer Corporation and Beckman
Instruments, Inc. (the “Sublicense Agreement”), Licensee failed to remit
certain monies owed to Applera under the Sublicense Agreement;

 

WHEREAS, without any admission of liability
with regards to the claims and counterclaims raised in the Lawsuits, the
Parties have executed, on even date herewith, that certain Settlement Agreement
to settle the Lawsuits to make a full and final compromise, settlement and
release of the claims and demands asserted, or that could have been asserted,
by the Parties in the Lawsuits (the “Settlement Agreement”);

 

WHEREAS, pursuant to the Settlement
Agreement, the Parties agreed to enter into certain other agreements, including
this Agreement, that are ancillary to the Settlement Agreement;

 

WHEREAS, Licensor owns U.S. Patent No. 6,814,934,
and other U.S. and non-U.S. patents and applications that claim priority from
United States application Serial No. 07/965,201, including European Patent
No. EP 872562 and Japanese Patent No. JP 3136129, that describe and
claim automated thermal cycling apparatus capable of performing and detecting
nucleic acid amplification in real time;

 

WHEREAS, Licensor owns U.S. Patents Nos.
5,038,852 and 5,333,675, describing and claiming automated apparatus suitable
for performing the PCR process, and apparatus claims in corresponding
counterpart patents and patent applications in other countries;

 

WHEREAS, Licensor owns U.S. Patent Nos.
5,475,610, 6,703,236 B2, and U.S. Patent Application Ser. No. 10/691,186
(Publication No. 2004/0248146 A2), describing and claiming improvements in
thermal cycling apparatus for PCR, including methods comprising calculating
sample temperatures (algorithm claims) and a pressing heated cover, and
corresponding counterpart patents and patent applications in other countries;

 

 

* Confidential Treatment
Requested by Celera Corporation*

HIGHLY
CONFIDENTIAL

EXECUTION
VERSION

 

WHEREAS, Licensor owns U.S. Patent No. 5,656,493,
describing and claiming an amplification system comprising PCR reagents and a
thermal cycler programmed to carry out a PCR protocol;

 

WHEREAS, Licensor owns patents and
applications outside the U.S. that claim priority of U.S. application Serial No. 06/899,061
(filed in 1986) and that claim automated performance of the PCR process using
certain programmed thermal cyclers; and

 

WHEREAS, Licensee has requested and Licensor
is willing to grant Licensee a license, pursuant to the terms and conditions
herein, under said patent rights worldwide.

 

NOW, THEREFORE, in consideration of the
premises and the mutual covenants and promises contained herein, and for other
good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged by the Parties, the Parties, intending to be legally bound, hereby
covenant and agree as follows:

 

1                                        Definitions

 

For the purpose of this Agreement the terms
set forth hereinafter shall be defined as follows:

 

1.1                                “Affiliate” shall mean, with respect to a
Party, any corporation or other entity that is directly or indirectly
controlled by, under common control with, or that controls such Party. For the
avoidance of doubt, any such corporation or other entity shall cease to be an “Affiliate”
of such Party under this Agreement when such corporation or other entity is no
longer directly or indirectly controlled by, under common control with, or
controlling such Party. For purposes of this definition, “controls,” “control”
and “controlling” mean the direct or indirect ownership or control (whether
through contract or otherwise) of more than fifty percent (50%) of the stock or
shares entitled to vote for the election of directors in the case of corporate
entities and in the case of non-corporate entities, more than fifty percent
(50%) of the equity interest with the power to direct management policies;
provided that, if local law restricts the maximum ownership interest of foreign
interests to less than fifty percent (50%), control will be established by
direct or indirect beneficial ownership of one hundred percent (100%) of the
maximum ownership percentage that may be owned by foreign interests under such
local law.

 

1.2                                “Algorithm
and Heated Cover Patent Rights” shall mean (a) Valid Claims of
U.S. Patent Nos. 5,475,610 and 6,703,236, and Valid Claims of U.S. Patent
Application Publication No. U.S. 2004/0248146 A2, and (b)  any Valid
Claims in foreign patents and patent applications that claim priority from any
of the applications for patent that resulted in U.S. Patent No. 5,475,610,
or U.S. Patent No. 6,703,236, and U.S. Patent Application Publication No. U.S.
2004/0248146 A2.

 

1.3                                “Amplification
System Patent Rights” shall mean (a) Valid Claims of U.S.
Patent No. 5,656,493 and (b) any Valid Claims in any foreign patent
or patent application that claim priority from any of the applications for
patent that resulted in U.S. Patent No. 5,656,493.

 

1.4                                “Applied Markets” shall mean (a) quality
assurance and quality control, including, without limitation, conformance with
specifications, purity and batch to batch consistency; (b) testing and
monitoring of environmental and food samples; (c) identity 

 

2

 

* Confidential Treatment Requested by Celera Corporation*

HIGHLY
CONFIDENTIAL

EXECUTION
VERSION

 

testing (including, without limitation, for humans, animals, plants,
organisms, microbes or their remains); (d) epidemiology; and (e) biosecurity.

 

1.5                                “Automated
Method Patent Rights” shall mean automated method Valid Claims in
Licensor’s patents and patent applications outside the U.S. that claim priority
from U.S. Application Serial No. 899,061.

 

1.6                                “Covenanted
Patents” shall mean (a) Valid Claims of U.S. Patent Nos. [***]
and [***], (b) any Valid Claims in any foreign patent or patent
application thereof that claim priority from any of the applications for patent
that resulted in U.S. Patent No. [***] or [***], and (c) any
continuations, continuations-in-part (but only to the extent of any claims
therein that claim priority from any of the foregoing in parts (a) and (b) above),
divisionals, reissues, re-examinations, extensions, provisionals, substitutes
or renewals of any of the foregoing in parts (a) and (b) above, but
only to the extent any of the foregoing claims any instrument, process or
system, and all patents issuing from any of the foregoing in this part (c).

 

1.7                                 [INTENTIONALLY LEFT
BLANK]

 

1.8                                “Exploit” shall mean make, use, sell, offer
to sell, import, export, practice any method and the exercise of all other
activities with regards to which relief for infringement of patent rights may
be obtained under Title 35 of the United States Code and foreign equivalents
thereto (as the foregoing may be amended or superseded from time to time),
except that Exploit shall not include any “have made” activities (except by
Licensor or Licensee’s Affiliates). “Exploited,” “Exploitation” and other variants or variations of the word “Exploit” shall have correlative meanings.

 

1.9                                “Licensed Field” shall mean Licensed Products
and processes for the use thereof, that are neither sold nor used in the
Applied Markets that:

 

(A)                              (i) when sold or
used in the United States, are designed, developed and manufactured in
accordance with the Quality Systems Regulations (as promulgated by the United
States Food and Drug Administration, and set forth in the Code of Federal
Regulations (“CFR”) at 21 CFR Part 820, and as may be amended from time to
time) or (ii) when sold or used in Europe, are designed, developed and
manufactured in accordance with the ISO 13485 standard (as promulgated by the
International Organization for Standardization, and as may be amended from time
to time) or are certified to be compliant with European Directives on in vitro
diagnostic medical devices (IVD-D), or (iii) when sold or used in other
jurisdictions, satisfy the applicable regulatory requirements relating to in
vitro human diagnostic products;

 

(B)                                are
designed, configured, promoted and intended for use with a menu of
Licensee-provided diagnostic kits that are approved, compliant or are otherwise
cleared by the appropriate regulatory authority in each jurisdiction where the
instrument is used or sold; and

 

(C)                                in
the U.S., may also be used for Licensee-provided Analyte Specific Reagents, as
such term is defined pursuant to 21 CFR 809 and 21 CFR 864.4020.

 

1.10                          “Licensed Patents” shall mean: (a) the Algorithm and
Heated Cover Patent Rights, the Amplification System Patent Rights, the
Automated Method Patent Rights, the Real-Time Apparatus Patent Rights and the
Thermal Cycling Instrument Patent Rights; (b) any

 

3

 

* Confidential Treatment Requested by Celera Corporation*

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

continuations, continuations-in-part (but only to the extent of any
claims entitled to claim priority from any of the applications that resulted in
the patents in the foregoing in part (a) above), divisionals, reissues,
re-examinations, extensions, provisionals, substitutes or renewals of any of
the foregoing in part (a) above, but only to the extent any of the
foregoing claims any instrument, process or system, and all patents issuing
from any of the foregoing in this part (b); and (c) [***]. No other
patents or patent applications are included within the definition of Licensed
Patents. Notwithstanding anything herein to the contrary, a non-exhaustive list
of patents that are excluded from the Licensed Patents are the patents set
forth on Exhibit I attached hereto and also excluded from the Licensed
Patents are, with the exception of the Real-Time Apparatus Patent Rights, U.S.
Patent Nos. 5,475,610, 6,703,236, 5,656,493, 5,038,852, and 5,33,675, any
patents and patent applications claiming priority from the patents on Exhibit I
or having common priority claims as the patents on Exhibit I. “Licensed
Patents” do not include rights under any other patent or patent application,
and expressly exclude, by way of example only, patents and patent applications
that cover real-time methods or cover reagents, kits, mixtures or systems that
are capable of use with Licensed Real-Time Thermal Cyclers.

 

1.11                          “Licensed Product” shall mean a Licensed Real-Time Thermal
Cycler, including any components, replacement parts, upgrades, computer
software or hardware for or in the foregoing, the Exploitation of which would,
but for the rights granted under this Agreement, infringe at least one Valid
Claim of the Real-Time Apparatus Patent Rights.

 

1.12                           [INTENTIONALLY LEFT BLANK].

 

1.13                          “Licensed Real-Time Thermal Cycler” shall
mean a Real-Time Thermal Cycler the Exploitation of which would, but for the
license granted herein, infringe at least one Valid Claim of the Real-Time
Apparatus Patent Rights. A Licensed Real-Time Thermal Cycler is a complete
instrument, including, for instance, a computer and basic software used for
controlling the instrument and collecting data.

 

1.14                          “Net Sales Price” shall mean (a) in the case of an arm’s-length
transaction to an unrelated Third Party end user not enjoying any special
course of dealing with Licensee or its Affiliates, wherein the end user Third
Party is not providing any nonmonetary consideration and the gross invoice
price for a Licensed Product that is subject to royalty obligation under Article 3
herein is not affected by any other purchase of goods or services or any
license of intellectual property (other than the end user rights conveyed
pursuant to Article 2 of this Agreement): the gross invoice price for such
sale of such Licensed Product (together with any associated warranty coverage
sold) to an end user Third Party by Licensee or its Affiliates of such Licensed
Product, minus the following deductions where applicable: (i) discounts
allowed and taken, in amounts customary in the trade, and (ii) sales
and/or use taxes and/or duties for particular sales. No allowance or deduction
shall be made for commissions or collections, by whatever name known;

 

4

 

* Confidential Treatment Requested by Celera Corporation*

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

(b) subject to Section 3.3, in the case of a transaction to a
distributor that is not an Affiliate of Licensee, [***]. No allowance or
deduction shall be made for commissions or collections, by whatever name known;
and

 

(c) in the case of a sale, loan, lease, consignment, distribution
or transfer of Licensed Products subject to royalty obligations under Article 3
herein that is not within the scope of Section 1.14(a) or 1.14(b):
the Average Net Sales Price (as such term is defined below) for sales to end
users for such Licensed Product calculated under Section 1.14(a). Without
limiting the foregoing, Net Sales Price shall be calculated as set forth in
this Section 1.14(c) in the event of any sale, loan, lease,
consignment, gift, distribution or other transfer (i) to a party that is
Licensee itself or an Affiliate of Licensee or (ii) to a Third Party that
enjoys a special course of dealing with one or more of the Licensee or an
Affiliate of Licensee. In the case of a Reagent Rental of Licensed Products, however,
[***].

 

For the purposes of this definition, an arm’s-length sale to an
unrelated Third Party is one in which (i) such Third Party does not enjoy
any special course of dealing with Licensee or its Affiliates, (ii) such
Third Party does not provide any nonmonetary consideration for a Licensed
Product (under Article 3 herein), and (iii) the gross invoice price
in such sale of such Licensed Product is not affected by any other purchase of
goods or services or any license of intellectual property other than the end
user rights conveyed in Article 2 herein.

 

As used herein the term “Average Net Sales Price” shall mean (A) the
average of Net Sales Price for transfers under Section 1.14(a) over
the one year period preceding the date of transfer that is within this Section 1.14(c) of
the same type and model of Licensed Product and in the same country as such
transferee; (B) if such one-year average Net Sales Price data is
unavailable, then the seller’s (Licensee or its Affiliate) published end user
list price of such Licensed Product for end users in such country as the
transferee; or (C) if data is unavailable under part (A) or (B), then
the fair market value (with reference to the sales price of comparable
products).

 

1.15                          “Notice” shall mean the label statements affixed to Licensed
Products under Section 4.

 

1.16                          “Person” shall mean a(n) individual, corporation, trust,
partnership, limited liability company, joint venture, unincorporated
organization or other entity.

 

1.17                           [INTENTIONALLY LEFT BLANK]

 

1.18                          “Reagent Rental” shall mean an arrangement whereby a Licensed
Product is provided to a customer, where part of the consideration for the
customer obtaining such Licensed Product includes an ongoing reagent or
consumable purchase commitment on the part of a customer such that part of the
price for the reagents or consumables is attributable to the acquisition cost
or leasing cost of the Licensed Product, the cost of servicing the Licensed
Product and/or other items of cost recovery in connection with supply and
support of the Licensed Product; provided, however, that either (a) title
to such Licensed Product does not transfer to such customer (if at all) before
such customer has completely fulfilled its

 

5

 

* Confidential Treatment Requested by Celera Corporation*

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

purchase commitment for such reagents or consumables, or (b) such
customer’s continued right to use and possess such Licensed Product is
contingent upon such customer completely fulfilling its purchase commitment for
such reagents or consumables.

 

1.19                          “Real-Time
Apparatus Patent Rights” shall mean (a) Valid Claims of
Licensor’s U.S. Patent No. 6,814,934 and any reexamination or extension
thereof and (b) any Valid Claims in foreign equivalent patents and patent
applications thereof where such corresponding Valid Claims claim priority from
any of the applications for patent that resulted in U.S. Patent No. 6,814,934
or any reexamination or extension thereof that claims an instrument, process or
system (such as, by way of example only, EP 872562 and JP 3136129). “Real-Time
Apparatus Patent Rights” do not include rights under any other patent or patent
application, and expressly exclude, by way of example only, patents and patent
applications (a) that cover real-time methods or cover reagents, kits,
mixtures or systems that are capable of use with Licensed Real-Time Thermal
Cyclers or (b) that are set forth on Exhibit I.

 

1.20                          [INTENTIONALLY LEFT BLANK]

 

1.21                          “Real-Time
Thermal Cycler” shall mean an instrument, whether in single or
multiple modules, that includes a Thermal Cycler and a detector which can be
used to detect a fluorescence optical signal while the Thermal Cycler is in
operation and without opening the reaction chambers (for example, tubes,
microtitre plates, wells or depressions) in which amplification is occurring.

 

1.22                           [INTENTIONALLY LEFT BLANK]

 

1.23                          “Thermal
Cycling Instrument Patent Rights” shall mean (a) Valid Claims
of U.S. Patent Nos. 5,038,852 and 5,333,675, and (b) any Valid Claims in
foreign equivalent patents and patent applications thereof where such
corresponding Valid Claims claim priority from any of the applications for
patent that resulted in U.S. Patent No. 5,038,852 or U.S. Patent No. 5,333,675.

 

1.24                          “Territory”
shall mean the world.

 

1.25                          “Thermal
Cycler” shall mean an instrument, whether in single or multiple
modules, that is capable in itself of automatically cycling samples in the PCR
process, including any controlling hardware and software.

 

1.26                          “Third
Party” shall mean a party other than one of the Parties to this
Agreement.

 

1.27                          “Valid
Claim” shall mean a claim of an unexpired patent or pending patent
application that has not been held unpatentable, invalid or unenforceable
pursuant to a final and unappealable decision of a court or other applicable
administrative agency with appropriate jurisdiction.

 

2                                         License
Grant

 

2.1                                 Rights for Licensed
Products. Upon the terms and subject to the exceptions and conditions of
this Agreement, including without limitation Section 2.3, Licensor hereby
grants to Licensee under the Licensed Patents a personal, non-transferable (except as set forth
in Article 9), royalty-bearing, non-exclusive license in the Licensed
Field and in the Territory, with no rights to sublicense, to sell directly or
indirectly through distributors

 

6

 

* Confidential Treatment Requested by Celera Corporation*

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

(including
Licensee’s Affiliates) (subject to Section 2.3) and to otherwise Exploit, in
all cases under Licensee’s trademarks and trade names, Licensed Products in the
form of complete Licensed Real-Time Thermal Cyclers as well as any add-on,
substitute, repair and replacement components (including, without limitation,
software or hardware ), and not as a foundry or OEM manufacturer for Third
Parties. For the avoidance of doubt, nothing in this Section 2.1 precludes
Licensee or any of its Affiliates from integrating any Licensed Product into or
with any other instruments or components, provided that none of such
integration, other instrument(s) or component(s), resulting integrated system
or the use of such integrated system infringes any of Licensor’s patent rights
other than the Licensed Patents (but only to the extent of any claims of such
Licensed Patents that are infringed by such Licensed Product prior to any such
integration), and further provided that the foregoing does not convey or
constitute a license, immunity from suit or any other right under any claims of
the Licensed Patents other than with respect to the Exploitation of such
Licensed Product itself (and not such other instruments and components). For
the further avoidance of doubt, the foregoing right to sell directly or indirectly
through Licensee’s Affiliates includes the right of such Affiliates to import
or export Licensed Products from Licensee or any of its Affiliates.

 

2.2                                No Right to
Sublicense. Subject to Section 9.1, rights granted to Licensee by this
Agreement are personal to Licensee alone. Licensee shall have no right to
sublicense, assign or otherwise transfer or, subject to Section 2.3, share
its rights hereunder.

 

2.3                                Distributors;
Major Diagnostic Entities. Licensee’s and its Affiliates rights under Section 2.1
to sell through distributors is limited to selling through distributors that
are not Major Diagnostic Entities (as defined below). Licensee and its
Affiliates shall not collaborate with any Major Diagnostic Entity with respect
to the co-development of Licensed Products or systems that include Licensed
Products. As used herein, the term “Major Diagnostic Entity” and “Major
Diagnostic Entities” means any Third Party that had worldwide sales in the
field of molecular diagnostics of [***].

 

2.4                                No
Other Patent Rights or Other Rights Granted. Except as expressly set forth
in Article 5 herein, the license granted hereunder includes no right,
immunity, authorization or license, either expressly, by implication, by
estoppel or otherwise, under any patent or patent application that is not
included in the Licensed Patents. No right is granted to Licensee or its
Affiliates or its or their customers outside the Licensed Field.

 

3                                         Fees,
Royalties, Records and Reports

 

For licenses
and rights granted under Article 2, Licensee shall pay to Licensor:

 

3.1                                License Initiation Fee. In consideration of the license herein
and under that certain Diagnostic Field DNA Sequencing Sublicense Agreement
between the Parties executed on even date herewith (“Diagnostic Field DNA
Sequencing Sublicense Agreement”), Licensee shall pay Licensor a fee of twenty
million dollars ($20,000,000) paid at the rate of two million dollars
($2,000,000) per calendar quarter for ten (10) quarters. The payments shall be
due on the [***]. For the avoidance of doubt only a single fee of [***]

 

7

 

* Confidential Treatment
Requested by Celera Corporation*

HIGHLY CONFIDENTIAL

EXECUTION VERSION

 

[***] is due for both
this Agreement and the Diagnostic Field DNA Sequencing Sublicense Agreement.

 

3.2                                Licensed Products. Except as provided in Section 3.3,
for each Licensed Product sold, placed or otherwise transferred by Licensee or
its Affiliates (whether to an end user or distributor) on or after the
Effective Date hereto, Licensee shall pay to Licensor a royalty of [***] of the
Net Sales Price of such Licensed Product; and [***]. Notwithstanding anything
above in this Section 3.2 or elsewhere in this Agreement, the following
are [***].

 

3.3                                Reagent
Rental. For each Licensed Product sold, placed, leased or transferred by
Licensee or an Affiliate of Licensee [***] under a Reagent Rental, Licensee
shall pay to Licensor a royalty of [***]. Notwithstanding the foregoing or
otherwise, the [***] shall also apply in such instances where a Licensed
Product is sold, placed, leased or transferred to an end user as part of a
Reagent Rental by a distributor of Licensee or of an Affiliate of Licensee
provided that the Licensee or its Affiliate knows or becomes aware of such
Reagent Rental by such distributor.

 

3.4                                Currency.
All amounts payable hereunder shall be payable in United States dollars. Sales
in other countries shall be converted to U.S. dollars based on the New York
rate of exchange as quoted in the Wall Street Journal for the last business day
of the applicable quarter. If not so published, the Parties may agree on a
substitute publication. In the event there is no comparable publication, the
applicable rate for such date by the appropriate governmental agency in such
country shall apply. The Parties agree that, subject to Licensor’s prior
written consent (which consent shall not be unreasonably withheld), Licensee
may change the foregoing method of calculating currency conversion, provided
such new method is in accordance with Generally Accepted Accounting Principles
in the U.S.

 

3.5                                Maintenance
of Records; Audit. Licensee shall keep, and shall require its pertinent
Affiliates to keep, full, true and accurate records containing all particulars
necessary to calculate the amount payable to Licensor under this Agreement and
to demonstrate Licensee’s (and its Affiliates’) compliance with its obligations
under this Agreement. Such records and the supporting data shall be open at all
reasonable times, for [***] following the end of the calendar year to which
they pertain (and access shall not be denied thereafter, if reasonably
available), to the inspection of an independent certified public accounting
firm retained by Licensor. Such accounting firm will hold such records and
supporting data in strict confidence, except as necessary to consult with and
report to Licensor and Licensee on the accuracy and completeness of Licensee’s
and its Affiliates’ compliance with this Agreement. If in dispute, such records
shall be kept until the later of the expiration of the foregoing [***] period
or the date the dispute is settled. Inspection shall be at Licensor’s expense,
unless the inspector concludes that the amount payable that is stated in a
report is understated by [***] or more, in which case reasonable expenses shall
be paid by Licensee.

 

8

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

3.6                                Royalty Payments and Royalty
Reports. Licensee shall within [* * *] days after the first of January, April,
July and October deliver (by U.S. mail or nationally recognized
courier service with a text copy in MS-Excel format (or other reasonable format
requested in writing by Licensor) of such report transmitted by email to
royalties@appliedbiosystems.com) to Licensor a true and accurate royalty
accounting report. This report shall be on a country-by-country basis and shall
give such particulars of the business conducted by Licensee in each country
during the preceding three (3) calendar months as are pertinent to
accounting under this Agreement, and shall be in accordance with, and include
at least information specified in, the royalty report form attached hereto as Exhibit II,
as may be amended as mutually agreed upon by the Parties in writing from time
to time.

 

The
correctness and completeness of each report shall be attested to in writing by
a responsible financial officer of Licensee.

 

3.7                                Tax Withholding. Withholding
tax, if any, levied by a government of any country on the  payment made by Licensee to Licensor
hereunder shall be borne by Licensor. Licensee shall use reasonable commercial
efforts to enable Licensor, at Licensor’s expense, to claim exceptions
therefrom under any double taxation or similar agreement in force and shall
produce to Licensor proper evidence of payment of all withholding tax.

 

3.8                                Royalty Report and Payment
Address. Simultaneously with the delivery of each royalty account report (as
per the schedule set forth in Section 3.6), Licensee shall pay to Licensor
the monies then due under this Agreement for the period covered by the report.
Each report and payment shall be sent by the due date to the following address:

 

Applied
Biosystems

850
Lincoln Centre Drive

Foster City,
CA  94404

Attention:
Director of Licensing

 

or to any
address that Licensor may advise in writing thirty (30) days prior to its
becoming effective.

 

3.9                                Interest. If Licensee
fails to pay any amount owing under this Agreement by the due date, the amount
owed shall bear interest at [* * *] from the due date until paid, provided,
however, that if this interest rate is held to be unenforceable for any reason,
the interest rate shall be the maximum rate allowed by law at the time the
payment is due.

 

4                                        License
Notice

 

Patent Notice. Licensee agrees to mark or
cause its applicable Affiliate to mark each Licensed Product and include
prominently in the corresponding user’s manual, but not any other Thermal
Cycler or manual therefor, a Notice to purchaser as specified from time to time
by Licensor. Unless and until Licensor instructs differently (upon which
instruction Licensee will implement the new Notice within a commercially
reasonable timeframe not to exceed one hundred eighty (180) days after
Licensee’s receipt of such instruction), the Notice shall be:

 

9

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

NOTICE
TO PURCHASER

 

This
Real-Time Thermal Cycler is licensed for use solely in the field of human vitro
diagnostics under one or more of U.S. Patents Nos. 6,814,934, 5,038,852,
5,656,493, 5,333,675, 5,475,610, 5,602,756, and 6,703,236, or corresponding
claims in their non-U.S. counterparts, owned by Applera Corporation. No other
field of use (e.g., the research field) is permitted. No right is conveyed
expressly, by implication or by estoppel under any other patent claim, such as
claims to apparatus, reagents, kits, or methods such as 5’ nuclease methods. For
further information on purchasing licenses, contact the Director of Licensing
at Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404,
USA.

 

5             Covenant Not to
Sue

 

5.1                                Covenant.
Upon the terms and subject to the exceptions and conditions of this Agreement,
Licensor grants to Licensee a personal, non-transferable (except as set forth
in Article 9), royalty-free, fully paid-up, non-exclusive covenant not to
sue: (a) Licensee or any of its Affiliates or distributors (excluding all
distributors that are Major Diagnostic Entities) for infringement of any of the
Covenanted Patents in the Licensed Field and in the Territory based on Licensee’s
exercise of the license set forth in Article 2 herein (including, Licensee’s
and its Affiliates’ making, using or selling of Licensed Products in the
Licensed Field pursuant to Article 2) and solely to the extent of Licensee’s,
its Affiliates’ or distributors’ activities that do not exceed the scope of the
license set forth in Article 2 herein; and (b) any end user of any
such Licensed Products described in part (a) above that has purchased or
otherwise obtained the same from Licensee 
(or a distributor or Affiliate of Licensee described in part (a) above)
for infringement of any of the Covenanted Patents in the Licensed Field and in
the Territory based on such end user’s use (solely to the extent within the
scope of the license granted hereunder and in accordance with the terms and
conditions of this Agreement) of such Licensed Products. The foregoing covenant
not to sue granted by Licensor to Licensee in this Section 5.1 shall,
subject to termination of this Agreement pursuant to Article 6 below, be
in effect until the longer of (i) the expiration of the last-to-expire
patent included in the Covenanted Patents, or (ii) the applicable statute
of limitations for enforcement of such Covenanted Patents. Without limiting the
foregoing covenant not to sue distributors or end users, the foregoing covenant
not to sue does not extend to any infringing activities of any Third Party that
occurred prior to the date such Third Party becomes a Licensee Affiliate.

 

5.2                                No
Other Rights Granted. Except as expressly set forth in Article 2
herein, this Agreement does not grant any right, immunity, authorization or
license, either expressly, by implication, by estoppel or otherwise, under any
patent or patent application that is not included in the Covenanted Patents. No
right is granted to Licensee or its Affiliates or its or their customers
outside the Licensed Field.

 

6                                        Term
and Termination

 

6.1                                Term.
This Agreement (and the licenses and royalty obligations hereunder), unless 

 

10

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

sooner
terminated pursuant to this Article 6, shall continue until the date of
expiration of the last-to-expire of the Licensed Patents and the Covenanted
Patents.

 

6.2                                Termination by Licensee. Licensee may
terminate this Agreement for any reason by giving written notice to Licensor
and ceasing to label, advertise or promote any Licensed Products as being
licensed hereunder. Such termination shall be effective [***] after said notice
or cessation of Licensee’s activities licensed hereunder, whichever is later.
During such [***] interval Licensee shall either sell or destroy its remaining
inventory of Licensed Products. Within [***] after the effective date of such
termination, Licensee shall provide Licensor with a royalty report and payment
as per Article 3 along with a certification signed by a company officer
that Licensee no longer has any inventory of Licensed Products.

 

6.3                                Insolvency. This
Agreement shall terminate immediately without Licensee having a right to cure
upon: (a) an adjudication of Licensee as bankrupt or insolvent, or
Licensee’s admission in writing of its inability to pay its obligations as they
mature; (b) an assignment by Licensee for the benefit of creditors; (c) the
appointment of, or Licensee’s applying for or consenting to the appointment of,
a receiver, trustee or similar officer for a substantial part of its property; (d) the
institution of or any act of Licensee instituting any bankruptcy, insolvency
arrangement, or similar proceeding; or (e) the issuance or levy of any
judgment, writ, warrant or attachment or execution or similar process against a
substantial part of the property of Licensee, including, but not limited to,
the rights and licenses granted under this Agreement.

 

6.4                                [INTENTIONALLY LEFT BLANK]

 

6.5                                Termination for Licensee’s
Material Breach. In the event Licensee materially breaches this
Agreement, then without limiting Licensor’s legal or equitable remedies, this
Agreement shall terminate automatically [***] (in the event of a breach of any
payment obligations under this Agreement) or [***] (in the event of any other
material breach of this Agreement) after Licensor provides notice thereof to
Licensee, provided that Licensee fails to cure such material breach within such
[***] or [***] period, respectively. Any failure by Licensee to perform any
payment obligation, or provide a timely and compliant royalty report, as and
when due under this Agreement shall be deemed a material breach of this
Agreement, subject to cure as stated herein, except that the third or any
subsequent occurrence of a failure under this sentence shall not be subject to
cure, if Licensor has given written notice of such failure each time and the
third such notice so specifies. Without limiting the foregoing, in the event a
distributor of Licensee or any of its Affiliates sells Licensed Products
outside of the scope of the license granted under Article 2, Licensee
shall have [***] from Licensee’s receipt of notice from Licensor (which notice
shall identify such distributor and a detailed description of the infringing
activity) to cause such distributor to cease further infringing sales of
Licensed Products.

 

6.6                                Effect of Termination or
Expiration. Upon expiration or termination of this Agreement,
all licenses and covenants not to sue granted to Licensee and its Affiliates
and their respective distributors herein shall terminate.

 

11

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

6.7                                Licensee’s Obligations
Surviving Termination. The termination or expiration of this
Agreement for any reason shall be without prejudice to any rights that shall
have accrued to the benefit of a Party prior to or on account of such
termination or expiration. All remedies provided hereunder or elsewhere
(including under applicable law) are cumulative. Licensee’s obligations to
report and pay royalties as to activities under this Agreement, and Licensor’s right to audit under Section 3.5,
shall survive termination or expiration. Without limiting the survival of other
Sections herein that expressly survive termination or expiration, Articles 1,
8, 10 and 11 and Sections 3.7, 6.6, this 6.7 and 7.3 shall survive any
termination or expiration of this Agreement.

 

6.8                                Termination by
Licensor. Without limiting Licensor’s remedies under the
Settlement Agreement and notwithstanding the provisions of Section 6.5,
Licensor shall have the right to terminate this Agreement, effective
immediately upon written notice to Licensee without any right for Licensee to
cure, where such termination is legally permissible and enforceable under
patent and competition laws (including under patent misuse and antitrust laws
in the United States), if Licensee or any of its Affiliates directly or
indirectly (e.g., with or through support of or supporting a Third Party)
challenges the validity or enforceability of any of the Licensed Patents in any
country in which the Licensed Patents are licensed to Licensee. For the
avoidance of doubt, the act of responding to a Third Party subpoena for
documents or for the taking of a deposition of Licensee or any of its
Affiliates or their respective employees shall not, in and of itself, be
considered as an indirect challenge to validity or enforceability of the
Licensed Patents.

 

7                                        Advertisements; Publicity; Confidentiality

 

7.1                                Advertisements. Unless and
until Licensor instructs differently (upon which instruction Licensee will
implement the new statement in a commercially reasonable time not to exceed [***]
after Licensee’s receipt of such instructions)  in advertisements,
catalogs, brochures, sales literature and promotional literature for Licensed
Products, Affiliates and distributors shall state the following prominently in
type and location:

 

This is a Licensed Real-Time Thermal Cycler(s)   under one or more of US Patents Nos.
6,814,934, 5,038,852, 5,656,493, 5,333,675, 5,475,610, 5,602,756, and
6,703,236, or corresponding claims in non-U.S. counterparts thereof, solely for use
in the field of human in vitro diagnostics. No other use is permitted. No right
is conveyed expressly, by implication or by estoppel under any other patent
claim.

 

7.2                                Publicity.
With respect to Licensee’s distribution of any written information to Third
Parties, including but not limited to advertising, brochures, catalogs,
promotional and sales material, and public relations material, Licensor
shall have the right to prescribe changes regarding references to, or
descriptions of:  Licensor, Applied
Biosystems group, Celera Genomics group, the patents under which rights are
granted in this Agreement, or this Agreement. Licensee agrees to comply with
Licensor’s reasonable prescriptions in a commercially reasonable time not to
exceed [***] after Licensee’s receipt of such prescriptions.

 

12

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

7.3                                Confidentiality. Except as
provided in Sections 7.1 and 7.2, Licensee shall maintain the confidentiality
of the provisions of this Agreement and shall refrain from disclosing the terms
of this Agreement without the prior written consent of Licensor during the term
of this Agreement and for a period of [***] after the end of the last-to-expire
of the Licensed Patents and Covenanted Patents under this Agreement, except to
the extent such disclosure is required under applicable law or regulation
provided that (a) such disclosure is limited to the information that must
be so disclosed under applicable law or regulation; and (b) Licensee
notifies Licensor of such requirement and the text of the proposed disclosure
at least [***] before such proposed disclosure is required (or, if such
proposed disclosure is required in less than [***], as far in advance of the
date of disclosure as is reasonably possible) and allows Licensor a reasonable
opportunity to comment upon, object or seek a protective order or other
injunctive relief to prevent or limit such disclosure. Licensor shall
be permitted to name Licensee in any published list of licensees under the
Licensed Patents, for example, in a list published on Licensor’s website. The
foregoing notwithstanding, either Party may issue a press release announcing
execution of this Agreement, provided that said press release is reasonably
acceptable to the other Party and is included in this Agreement as an Exhibit.

 

8                                        Compliance
and Quality

 

8.1                                Compliance
with Applicable Law. In the exercise of any and all rights granted to
Licensee and its Affiliates hereunder and in performance hereunder by Licensee
and its Affiliates and distributors, as between Licensor and Licensee, it shall
be the duty of Licensee, not Licensor, to comply fully with all applicable
laws, regulations and ordinances and to obtain and keep in effect licenses,
permits and other governmental approvals (federal, state or local) necessary or
appropriate for Licensee and its Affiliates and distributors to carry on
activities hereunder.

 

8.2                                No
Endorsement. Licensor does not approve or endorse any Licensed Product of
Licensee in any way or for any purpose, including for real-time PCR. Quality
and quality control with respect to Licensed Products (including suitability
for real-time PCR), according to standards and requirements that may exist in
the marketplace from time to time, are the sole responsibility of Licensee.

 

9                                        Assignment

 

9.1                                Assignment by Licensee. This Agreement
cannot be assumed or assumed and assigned by a trustee or debtor-in-possession
in bankruptcy as set forth in Section 365(c)(1) of the United States
Bankruptcy Code or any similar provisions of state or federal law. In addition,
this Agreement shall not be assigned or transferred by Licensee without the
Licensor’s express written consent (which consent shall be in Licensor’s sole
discretion), except that Licensee may assign or transfer this Agreement without
Licensor’s consent in connection with the sale or transfer of all or
substantially all of Licensee’s business to which this Agreement relates, stock
or assets (whether by merger, acquisition or otherwise). Any assignment or
transfer or attempted assignment or transfer of this Agreement (except as
permitted under this Section 9.1) shall be void ab initio
and result in the immediate and automatic termination of this Agreement without
any requirement of notice or other action by Licensor. In the event of an
internal reorganization or spin- 

 

13

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

off
of all or substantially all of Licensee’s research products-related business,
Licensee’s human diagnostics-related business and/or Licensee’s nucleic acid
analysis-related business resulting in any or all of such businesses being
conducted through a separate company or separate companies (“Spin-Off”), then
Licensee shall elect which of such companies shall continue to have all rights,
benefits and obligations of Licensee under this Agreement (including all
licenses and covenants not to sue granted by Licensor), up to a maximum of two (2) licensees.
Subject to the foregoing in this Section 9.1, any such resulting licensee
shall not have the right to further transfer any of its rights, benefits or
obligations under this Agreement.

 

9.2                                Assignment by Licensor. Licensor may
assign or transfer all of its rights and obligations under this Agreement at
any time without the consent of Licensee. Licensee agrees to execute such
further acknowledgements or other instruments as Licensor may reasonably
request in connection with such assignment.

 

10                                 Negation
of Warranties, Representations and Indemnification

 

10.1                        No
Warranty; No Implied Rights. Nothing in this Agreement shall be construed
as:  (a) a warranty or
representation by Licensor as to the validity, enforceability or scope of any
patent; (b) a warranty or representation that the exercise of the license
hereunder or the Exploitation of any Licensed Product pursuant to this
Agreement is or will be free from infringement of patents or other intangible
rights of Third Parties; or a warranty or representation that the practice (or
Exploitation of Licensed Products) under the Licensed Patents or Covenanted
Patents is or will be free from infringement of patents of Third Parties; (c) an
obligation by Licensor to file any patent application, secure any patent, or
maintain any patent in force; (d) any obligation of Licensor to prosecute,
enforce or sublicense its patent rights to (or against) Third Party infringers;
(e) except as expressly set forth herein, conferring upon Licensee the
right to use in advertising, publicity or otherwise, in any form, the name of,
or any trademark or trade name of, Licensor or any of its Affiliates; (f) granting
by implication, estoppel, or otherwise, any license, immunity or rights under
patents, trade secrets, know-how, copyrights, or other intangible rights of
Licensor other than the express licenses granted under the Licensed Patents
pursuant to Article 2 and the express covenant not to sue granted with
respect to the Covenanted Patents pursuant to Article 5, regardless of
whether any such patent or intangible right is dominant or subordinate to the
patents under which rights are granted in this Agreement; (g) an
obligation to furnish any know-how; or (h) creating any agency,
partnership, joint venture or similar relationship between Licensor and
Licensee.

 

10.2                        EXCEPT
AS EXPRESSLY STATED HEREIN, LICENSOR DOES NOT MAKE BUT EXPRESSLY DISCLAIMS
EXPRESS OR IMPLIED WARRANTIES OF ANY KIND (INCLUDING, WITHOUT LIMITATION, ANY
WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR
NONINFRINGEMENT) WITH RESPECT TO THE LICENSED PATENTS, THE COVENANTED PATENTS,
THE PRACTICE OF THE LICENSE HEREUNDER OR THE MAKING OR EXPLOITATIONS OF
PRODUCTS LICENSED HEREUNDER OR COVERED BY THE COVENANT NOT TO SUE GRANTED
HEREUNDER. IN NO EVENT SHALL LICENSOR BE LIABLE HEREUNDER FOR ANY SPECIAL, 

 

14

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

PUNITIVE,
INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST
PROFITS).

 

10.3                          Indemnification.
Licensee shall assume full responsibility for its operation under the Licensed
Patents and Covenanted Patents under which rights are granted in this
Agreement, the manufacture of Licensed Products and the use thereof and shall
defend, indemnify and hold Licensor harmless from and against all liability,
demands, damages, expenses (including reasonable attorneys’ fees) and losses
for infringement of Third Party intellectual property rights, death, personal
injury, illness, property damage or any other injury or damage, including any
damages or expenses arising in connection with state or federal regulatory
action (collectively, “Claims”) arising from Licensee’s and its Affiliates’ and
their respective distributors’ Exploitation of any Licensed Products, except to
the extent any Claims are caused solely by Licensor’s negligence or intentional
misconduct.

 

10.4                          Licensor.
Licensor represents and warrants to Licensee that Licensor: (a) owns
or has a license under the Licensed Patents and the Covenanted Patents; and (b) has
the right to grant the licenses, sublicenses and covenants not to sue, as the
case may be, as provided in this Agreement, under the Licensed Patents and the
Covenanted Patents in the Licensed Field.

 

10.5                          Licensee
Representations and Warranties. Licensee represents and warrants to Licensor
that Licensee has not, to a material extent, Exploited any product that would
be licensed hereunder if any of the foregoing actions in this Section 10.5
had occurred during the term of this Agreement, and that any such actions are
subject to the reporting and payment obligations in Article 3. Without
limiting Licensor’s causes of action or remedies, Licensee covenants for itself
and its Affiliates not to infringe, whether directly, by inducement, by
contribution or otherwise, the  Licensed
Patents by exceeding the scope of the license rights granted to Licensee and
its Affiliates pursuant to Article 2 hereunder.

 

11                                 Miscellaneous

 

11.1                        Integration. This Agreement
together with the Settlement Agreement constitutes the entire agreement between
the Parties as to the subject matter hereof, and all prior negotiations,
representations, agreements and understandings are merged into, extinguished by
and completely expressed by it. This Agreement may be modified or amended only
by a writing executed by authorized officers of each of the Parties.

 

11.2                        Notices. Any notice
required or permitted to be given by this Agreement shall be given by postpaid,
first class, registered or certified mail, or by overnight courier or by
facsimile, properly addressed to the other Party at the respective address as
shown below, and any notice provided under this Agreement shall be from:

 

If to or from
Licensor:

 

Applied
Biosystems

850
Lincoln Centre Drive

Foster
City, CA  94404

 

15

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

Attention:
Director of Licensing

Fax
No.:  (650) 638-6071

 

with a copy to:

 

Weil, Gotshal & Manges, LLP

201 Redwood Shores Parkway

Redwood Shores, CA  94065

Attn: Vern Winters, Esq.

Fax No.:  (650) 802-3100

 

If
to or from Licensee:

 

Beckman Coulter, Inc.

4300 North Harbor Boulevard

Fullerton, CA  92835

Attention:  Legal Department

Fax
No.:  (714) 773-7936

 

with a copy to:

 

Sheppard, Mullin, Richter & Hampton LLP

12544 High Bluff Drive, Suite 300

San Diego, CA  92130

Attn:  Amar L. Thakur, Esq.

Fax No.:  (858) 509-3691

 

Either Party
may change its address or the operating group providing notices under this
Agreement by providing notice to the other. A notice shall be deemed given four
(4) full business days after the day of mailing, or one full day after the
date of delivery to the courier, or the date of facsimile transmission, as the
case may be.

 

11.3                          Governing
Law. This Agreement shall be deemed made in the State of California, and it
shall be construed and enforced in accordance with the laws of the State of
California without regard to the conflict of laws provisions thereof.

 

11.4                          Binding Arbitration. All disputes
arising out of or otherwise related to this Agreement shall be exclusively
resolved through binding arbitration by three arbitrators selected by the
American Arbitration Association, in accordance with the American Arbitration
Association rules then in effect. Such binding arbitration shall be venued
in Los Angeles, California, if brought by Licensee, and shall be venued in San
Francisco, California, if brought by Licensor. The Parties shall equally share
the cost of such arbitration; provided, however, the arbitrator may award
attorneys fees and costs to the prevailing Party in such arbitration.

 

11.5                          Conflicting Provisions. Nothing in
this Agreement shall be construed to require the commission of any act contrary
to law, and wherever there is any conflict between any provision of this
Agreement or concerning the legal right of the Parties to enter into this 

 

16

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

contract
and any statute, law or ordinance, the latter shall prevail, but the provision
shall be limited only to the extent necessary.

 

11.6                          Severability.
If any provision hereof should be held invalid, illegal or unenforceable in any
respect, then, to the fullest extent permitted by applicable law: (a) all
other provisions hereof shall remain in full force and effect and shall be
liberally construed in order to carry out the intent of the Parties as nearly
as may be possible; and (b) the Parties agree to negotiate in good faith a
provision, in replacement of the provision held invalid, illegal or
unenforceable, that is consistent with applicable law and accomplishes, as
nearly as possible, the original intention of the Parties with respect thereto.
To the fullest extent permitted by applicable law, each Party hereby waives any
provision of law that would render any provision hereof prohibited or
unenforceable in any respect.

 

11.7                          Construction.
Except where the context otherwise requires, wherever used, the singular shall
include the plural and the word “or” is used in the inclusive sense. The
captions and headings of this Agreement are for convenience of reference only
and in no way define, describe, extend or limit the scope or intent of this
Agreement or the intent of any provision contained in this Agreement. Each
Party hereto and its counsel have participated fully in the review and
negotiation of this Agreement. Both Parties have participated equally in the
formation of this Agreement; the language of this Agreement shall not be
presumptively construed against either Party. As used herein “includes” and
related terms shall be deemed to be followed by the phrase “without limitation”.

 

11.8                          Independent
Contractors. It is expressly agreed that the Parties, shall be independent
contractors and that the relationship between the Parties shall not constitute
a partnership, joint venture or agency.

 

11.9                          Waiver.
The observance of any provision of this Agreement may be waived only by a
writing executed by an authorized officer of each Party. The waiver by either
Party hereto of any right hereunder or the failure to perform or a breach by
the other Party shall not be deemed a waiver of any other right hereunder or of
any other breach or failure by said other Party whether of a similar nature or
otherwise.

 

11.10                    Counterparts.
This Agreement may be executed (including via facsimile) in two (2) or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

 

11.11                    No Third
Party Beneficiaries. The representations, warranties, covenants, rights and
obligations set forth in this  Agreement
are for the sole benefit of the Parties and their successors and permitted
assigns, and they shall not be construed as conferring any rights on any Third
Parties.

 

11.12                    Bankruptcy
Code 365(n). The Parties acknowledge and agree that this Agreement is a
license of rights to “intellectual property” as defined under Section 101(56)
of the United States Bankruptcy Code. Except as expressly permitted by this
Agreement, this Agreement cannot be assumed and assigned by a trustee or
debtor-in-possession in bankruptcy as set forth in Section 365(c)(1) of
the United States Bankruptcy Code, or any similar provisions of state or
federal law.

 

17

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

11.13       Export Control
Regulations.  The rights and
obligations of the Parties under this Agreement shall be subject in all
respects to United States laws and regulations as shall from time to time
govern the license and delivery of technology and products abroad, including
the United States Foreign Assets Control Regulations, Transaction Control
Regulations and Export Control Regulations, as amended, and any successor
legislation issued by the Department of Commerce, International Trade
Administration, or Office of Export Licensing. 
Without in any way limiting the provisions of this Agreement, each Party
agrees that, unless prior authorization is obtained from the Office of Export
Licensing, it will not export, re-export, or transship, directly or indirectly,
to any country, any of the technical data disclosed to it by the other Party
hereto if such export would violate the laws of the United States or the regulations
of any department or agency of the United States Government.

 

11.14       No Admission of
Liability.  Notwithstanding anything
in this Agreement or otherwise, nothing in this Agreement constitutes an
admission by either Party of any infringement, validity or enforceability of
any of the Licensed Patents or Covenanted Patents.

 

[Signature Pages Follow.  The remainder of this page is
intentionally left blank.]

 

18

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

IN WITNESS
WHEREOF, the Parties hereto have caused this Agreement to be duly executed by
their respective authorized representatives, effective as of the Effective
Date.

 

	
  APPLERA
  CORPORATION,

  	
   

  	
  BECKMAN COULTER, INC.

  
	
  THROUGH ITS
  APPLIED

  	
   

  	
   

  
	
  BIOSYSTEMS
  GROUP AND

  	
   

  	
   

  
	
  CELERA
  GENOMICS GROUP

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Catherine M. Burzik

  	
   

  	
  By:

  	
  /s/ Paul Glyer

  
	
   

  	
  Catherine M. Burzik

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Title: President

  	
   

  	
  Title:

  	
  SVP Strategy and Business Development

  
	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
  June 30, 2006

  	
   

  	
  Date:

  	
  6/30/06

  
							

 

19

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

EXHIBIT
I

Exemplary
Patents Excluded from License Granted to Licensee(1)

 

	
  Amplification Patents

  	
   

  	
  5’ Nuclease and Probe Patents

  
	
  4,683,195*

  	
   

  	
  5,210,015

  
	
  4,683,202*

  	
   

  	
  5,219,727

  
	
  4,965,188*

  	
   

  	
  5,476,774

  
	
   

  	
   

  	
  5,487,972

  
	
  Polymerase Patents

  	
   

  	
  5,538,848

  
	
  5,352,600

  	
   

  	
  5,723,591

  
	
  5,618,711

  	
   

  	
  5,804,375

  
	
  5,789,224

  	
   

  	
  5,876,930

  
	
  6,127,155

  	
   

  	
  6,030,787

  
	
   

  	
   

  	
  6,214,979

  
	
  RT and RT-PCR Patents

  	
   

  	
  6,258,569

  
	
  5,310,652

  	
   

  	
   

  
	
  5,322,770

  	
   

  	
  Chemically-Modified Hot-Start Polymerase Patents

  
	
  5,407,800

  	
   

  	
  5,677,152
  (claims 24-30)

  
	
   

  	
   

  	
  5,773,258
  (claims 11-13)

  
	
  Sequencing Patents

  	
   

  	
   

  
	
  5,075,216

  	
   

  	
  dsDNA-Binding Dye Assay Patents

  
	
   

  	
   

  	
  5,994,056

  
	
  Taq Patent

  	
   

  	
  6,171,785

  
	
  4,889,818
  (non-US rights only)

  	
   

  	
   

  
	
  5,079,352

  	
   

  	
  Kit Patents

  
	
   

  	
   

  	
  6,040,166*

  
	
  Thermal Cycler Improvements

  	
   

  	
  6,197,563*

  
	
  6,555,792

  	
   

  	
  6,514,736*

  
	
  6,153,426

  	
   

  	
   

  
	
  5,942,432

  	
   

  	
  Optics

  
	
  6,719,949

  	
   

  	
   

  
	
  6,703,236

  	
   

  	
  6,563,581

  
	
  5,224,778

  	
   

  	
  6,211,989

  
	
  5,282,543

  	
   

  	
  6,744,502

  
	
  6,677,151

  	
   

  	
  6,839,179

  
	
  6,833,536

  	
   

  	
  6,982,166

  
	
  EP 1216098

  	
   

  	
   

  
	
  6,033,880

  	
   

  	
  Plastics for PCR

  
	
  5,456,360

  	
   

  	
  6,825,047

  
	
  6,638,761

  	
   

  	
  6,514,750

  
	
   

  	
   

  	
  6,942,836

  
	
   

  	
   

  	
  6,090,251

  
	
  Algorithms

  	
   

  	
   

  
	
  5,766,889

  	
   

  	
   

  

 

(1)The
tabulated patents are intended to be representative members of global patent
families having common priority claims that are to be excluded from the license
to Licensee hereunder.

 

*Expired.

 

20

 

* Confidential Treatment
Requested by Celera Corporation*

 

HIGHLY
CONFIDENTIAL

EXECUTION VERSION

 

EXHIBIT
II

 

Summary Royalty/Fee Report

REAL-TIME
INSTRUMENT PATENT LICENSE AGREEMENT

 

for the
Period:
                    
to                    
for Sales in the country of

 

Licensee:
                                  Effective
Date:
                    
Royalty/Fee Rate:

 

o   Check
here if there were no sales for this period.

 

	
  R-T TC

  Model

  	
   

  	
  No. of

  Units

  Sold

  	
   

  	
  Gross Invoice

  price (actual)

  	
   

  	
  Allowed

  Deductions

  (explain)

  	
   

  	
  Net sales

  Price (actual)

  	
   

  	
  Royalty Due

  (US$)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

	
  R-T TC

  Model

  	
   

  	
  No. of Units

  Sold

  	
   

  	
  Price to

  Distributor

  	
   

  	
  Calculated Net sales

  Price

  	
   

  	
  Royalty Due

  (US$)

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

I hereby certify the information set forth
above is correct and complete with respect to the amounts due under this
Agreement.

 

	
  By

  	
   

  	
   

  	
  Title

  	
   

  	
   

  	
  Date

  	
   

  

 

Name (please print)

 

Applera Corporation  Send report to: Director of
Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, CA 94404
USA

 

21Exhibit 10.24

 

*
Confidential Treatment Requested by Celera Corporation*

 

BERKELEY HEARTLAB, INC. AND DIADEXUS, INC.

MASTER
SUPPLY AGREEMENT

 

This Master Supply
Agreement, dated as of November 1, 2007, by and between diaDexus, Inc.
(“diaDexus”) and Berkeley HeartLab, Inc. (“Lab”), sets forth the terms and
conditions upon which diaDexus will sell to Lab, and Lab will purchase, various
products (the “Agreement”).  The parties
agree as follows:

 

A.           In
consideration of Lab purchasing from diaDexus the products specified in the
attached Product Addendum (“Products”) during the term of this Agreement,
diaDexus agrees to sell Products to Lab at the purchase prices set forth in the
attached Product Addendum.  Lab shall use
Products solely for performing in vitro clinical diagnostic testing on human
blood samples (“Permitted Use”).

 

B.             The
parties hereto acknowledge that this Agreement, including the exhibit and
addendum attached hereto, sets forth the entire agreement and understanding of
the parties as to the subject matter hereof and supersedes all prior and
contemporaneous discussions, agreements, and writings with respect hereto with
respect to the subject matter hereof. 
All previous agreements between diaDexus and Lab and Lab’s subsidiaries
will terminate as of December 31, 2006, other than surviving clauses.

 

C.             The
term of the Agreement shall commence on January 1, 2007 and expire on September
30, 2008 (the “Term”), unless extended for an additional three (3) months
by mutual consent in writing or terminated earlier pursuant to Paragraph N or
P.  Expiration or termination of this
Agreement for any reason will not release a party from any obligation that has
accrued prior to the effective date of such expiration or termination.  Paragraphs B, C, E, Q, R, S, T, U, V, W, X
and DD shall survive expiration or termination of this Agreement.

 

D.            diaDexus
shall ship Product(s) to Lab which orders such Product(s) under a
purchase order and which is authorized by the parties under this
Agreement.  Invoices shall be mailed to
the following address:

 

Berkeley
HeartLab, Inc.

Accounts
Payable Department

839
Mitten Road

Burlingame,
CA 94010

 

E.              Lab
shall pay diaDexus within forty-five (45) days after such invoice is received
by Lab.  In addition, Lab shall pay to
diaDexus the [***], as defined in the Product Addendum, in accordance with the
Product Addendum.  All applicable sales
or use taxes are the responsibility of Lab. 
In those states where diaDexus collects local/state sales taxes,
diaDexus will add these taxes to the invoices and after receipt of payment from
Lab, diaDexus shall remit such amounts to the appropriate taxing
authority(ies).  Any payment due and
payable under the terms and conditions of this Agreement made after the date
such payment is due and payable shall bear interest as of the 45th
day after the date such payment was due and payable and shall continue to
accrue such interest until such payment is made at a rate equal to the lesser
of the prime rate as reported by the Chase Manhattan Bank, New York, New York,
on the date such payment is due, plus an additional two percent (2%), or the
maximum rate permitted by law in the State of California. All payments made
under this Agreement shall be made in U.S. dollars, and such payments shall be
made by check or wire transfer to one or more bank accounts to be designated in
writing by diaDexus.  If payments are not
made, then orders will be placed on credit hold.

 

Term: January
1, 2007 - September 30, 2008

 

BHL/diaDexus_070919

 

1

 

*
Confidential Treatment Requested by Celera Corporation*

 

F.              Product
shipment shall be made FOB diaDexus’ domestic supply source.  Products will be shipped to the following
address:

 

Berkeley HeartLab, Inc.

960 Atlantic Ave, Suite #100

Alameda, CA 94501

Attn:  Lab
Manager

510-263-4088

 

G.             Except
as expressly provided herein, neither this Agreement nor any interest hereunder
will be assignable, nor any other obligation delegable, by a party without the
prior written consent of the other, which shall not be unreasonably withheld or
delayed; provided, however, that either party may assign this Agreement without
consent to any successor in interest by way of merger or sale of all or
substantially all of its assets in a manner such that the assignor will remain
liable and responsible for the performance and observance of all such party’s
duties and obligations hereunder. Any purported assignments made in violation
of this Paragraph G shall be null and void.

 

H.            Notices
and other communications permitted or required under this Agreement will be
deemed to be properly given when received by the other party and if given in
writing and either delivered by hand, overnight delivery service, or mailed by
First Class U.S. Mail, postage prepaid, addressed to the applicable party
as follows:

 

	
  diaDexus:

  	
   

  	
  diaDexus, Inc.

  
	
   

  	
   

  	
  343
  Oyster Point Boulevard

  
	
   

  	
   

  	
  South San Francisco, CA
  94080-1913

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Attention:
  Patrick Plewman

  
	
   

  	
   

  	
  President
  and Chief Executive Officer

  
	
   

  	
   

  	
   

  
	
  Lab:

  	
   

  	
  Berkeley
  HeartLab, Inc.

  
	
   

  	
   

  	
  839 Mitten Road

  
	
   

  	
   

  	
  Burlingame, CA 94010

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Attention:

  	
  Michael Mercer

  
	
   

  	
   

  	
   

  	
  Chief Commercial Officer

  
	
   

  	
   

  	
   

  
	
  With a copy to:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Berkeley
  HeartLab, Inc.

  
	
   

  	
   

  	
  839 Mitten Road

  
	
   

  	
   

  	
  Burlingame, CA 94010

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Attention: General Counsel

  

 

I.                 Products
shall be supplied in accordance with a  specification
for identity and quality of the Product as set forth in the PLAC® test Gen3
product insert (the “Specification”). 
The Specifications are considered a performance guaranty and represent
the expectation for the Product’s performance by Lab.  diaDexus shall give Lab a 90-day written
notification of any changes to the Specification.

 

Prior to using a Product
with changes in Specifications, or offering to Lab, Products for the Permitted
Use, diaDexus will, at its sole cost and expense, complete a full method
validation, according to CLSI accepted guidelines and present such data to Lab
for consideration.  Lab may conduct
further validation in collaboration with diaDexus.  diaDexus shall, at its expense, supply kits,
technical services and samples as reasonably required for such validation
testing, and Lab shall procure necessary equipment and reagents for such. Lab
shall also assign competent trained personnel appropriate for testing the
Products.  Lab shall perform the
validation testing and share results and data (which shall be Confidential
Information, subject to Paragraph V) as necessary with diaDexus to ensure that
all regulatory and quality control requirements have been met to mutual
satisfaction before shipment of Product(s) for 

 

BHL/diaDexus_070919

 

2

 

*
Confidential Treatment Requested by Celera Corporation*

 

Permitted Use.  The performance of Product in the Lab will
ultimately determine the acceptability of Product.  Lab has the right to reject the changes if
Product’s performance is deemed not acceptable.

 

diaDexus will guarantee
to Lab overnight delivery. If a shipment is received in which the Product
appears to have warmed during shipment (indicated by the cold packs being warm),
Lab will test the shipment at its discretion and inform diaDexus.  In such a case, diaDexus will bear the cost
for the return shipment and replacement of such Product.

 

Prior to using a Product
with a new lot number, Lab will perform acceptability studies.  Lab will perform correlation, linearity and
precision studies to determine acceptability using Lab’s established procedures
for these studies.  For the correlation
studies, a minimum of 60 samples spanning the Lab’s assay range for the Product
will be tested in a controlled side-by-side study, minimizing lab and operator
variables, and the average bias between the new Product lot and the previous
Product lot will have to be less than 13%, supported by appropriate statistical
analysis in order to be acceptable by Lab. 
For any analysis that does not meet Lab’s expectations, that analysis
shall be shared with diaDexus. The results of the precision studies must be
<8% CV for “within run/intra-assay precision” and the results of the
linearity studies must meet Lab achieved linearity of <20% average bias for
the obtained values compared to the expected values up to a range of 100-360
ng/mL.  Lab shall inform diaDexus of the
result of the acceptance inspection including the judgment of acceptance or
rejection of all or part of a shipment in writing within ten (10) business
days after the receipt of such shipment of Product.  If Lab fails to notify diaDexus of a
rejection within such ten (10) business day period, the shipment of
Product shall be deemed accepted by Lab. 
For clarity, Lab shall have no right to reject any Product that is not
stored as required by the Specification during the thirty (30) day period
beginning upon Lab’s receipt of Product.

 

In the event that
diaDexus receives a notice of rejection from Lab in accordance with this
Paragraph I, diaDexus, shall use all best efforts to replace any shipment of
such rejected Product within fifteen (15) days  after
receiving Lab’s written notice of rejection. 
Lab shall keep such defective Products at its premises until the earlier
of (a) thirty (30) days or (b) receipt of diaDexus’ instruction for
return or disposal of such defective Products and shall return or dispose of
such defective Products in accordance with such instruction.  If Lab is instructed to (i) return such
defective Products, diaDexus shall assign Lab a return goods authorization
(RGA) number, shall provide shipping instructions for such return and shall
reimburse Lab for any reasonable freight charges associated with such return or
(ii) to dispose of such defective Products, diaDexus shall reimburse
Lab for any costs associated with such disposal.  Notwithstanding anything to the contrary,
diaDexus shall have no obligation to replace any shipment of Product pursuant
to this Paragraph I if such defect occurred after Lab’s receipt of such Product
from diaDexus, unless such defect is of a nature that could not be discovered
during Lab’s acceptability study (such defect shall be referred to as a “Latent
Defect”).  In the event of any Latent
Defect, Lab may revoke its acceptance of such defective Products by providing
written notice thereof to diaDexus within ten (10) days of discovering
such Latent Defect.  Notwithstanding
anything to the contrary in this Agreement, the parties acknowledge that replacement
of defective Products pursuant to this Paragraph I and indemnification under
and pursuant to Paragraph R shall be the sole and exclusive remedy of Lab for
any Product defects, including breach of the warranty set forth in Paragraph Q.

 

If diaDexus disputes Lab’s right to reject any
shipment of Product as set forth in this Paragraph I, diaDexus shall notify Lab
within twenty (20) days after such rejection. 
Such dispute shall be resolved by a third party, the identity of whom
shall be mutually agreed upon by the parties, and the appointment of whom shall
not be unreasonably delayed by either party. 
The determination of such third party with respect to any shipment of
Product shall be final and binding upon the parties, but only as to the reasons
given by Lab in rejecting the shipment and shall have no effect on any matter
for which such third party did not make a determination.  The fees and expenses of such third party
shall be paid by the party against which the determination is made.

 

Lab shall reasonably
cooperate with diaDexus in the performance of periodic quality control surveys
as requested by diaDexus to ensure that Products are used for the Permitted Use
and meet regulatory requirements.  Lab
hereby agrees to discuss technical performance and collaboratively resolve any
problems with diaDexus technical support personnel, provided that all such
personnel execute reasonable non-disclosure and non-use agreements, as may be
requested by Lab.

 

diaDexus shall provide
competent trained personnel to assist Lab with Technical issues that may arise
from time to time and to address technical issues associated with performance
of the Product.

 

BHL/diaDexus_070919

 

3

 

*
Confidential Treatment Requested by Celera Corporation*

 

J.                Lab
will provide diaDexus with monthly testing volume reports sorted by [***] in
the Snapshot Report and the Final Report.

 

K.            This
Agreement may not be amended or modified except by written agreement of both of
the parties.

 

L.              diaDexus
will not be liable for any failure to perform under this Agreement due to
strikes, fire, explosion, flood, riot, lock-out, injunction, interruption of
transportation, unavoidable accidents, or inability to obtain supplies at
reasonable prices.

 

M.         In
the event that a Product is unavailable, diaDexus will notify Lab of such
unavailability by written or electronic communication, and diaDexus will,
within the course of fifteen (15) working days, notify Lab of an action plan to
correct the problem.

 

N.            This
Agreement may be terminated by either party with or without cause at any time
with ninety (90) days written notice.

 

O.            Items
defined as Products listed on the Product Addendum or added on the Product
Addendum at a later date will have guaranteed pricing through the term of the
Agreement.

 

P.              If
any term of this Agreement is breached materially by either party and the
parties cannot agree on a resolution, the non-breaching party may terminate
this Agreement if the breach is not cured within 30 days after notice is given
in accordance with Paragraph H.

 

Q.            diaDexus
represents and warrants to Lab that the Products supplied shall (i) not be
adulterated or misbranded by diaDexus within the meaning of the U.S. Food,
Drug, and Cosmetic Act; (ii) be produced in accordance with the U.S. Food,
Drug and Cosmetic Act Quality System Requirements, specifically 21 CFR Part 820;
and (iii) function in accordance with the Specifications supplied by
diaDexus in connection with such Products after inspection and acceptance by
Lab in accordance with Paragraph I; provided that Lab maintains and
stores such Products in accordance with instructions contained in such
documentation.  diaDexus hereby
represents and warrants that, to the best of its knowledge, the practice of any
technology or patents comprising the Product that are licensed hereunder is and
will be free of any infringement of patents of other persons.  EXCEPT AS SPECIFICALLY SET FORTH IN THIS
PARAGRAPH Q, DIADEXUS MAKES NO REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS
OR IMPLIED, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, ANY
WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR USE, ANY WARRANTY OF
NON-INFRINGEMENT, ANY WARRANTY OF SAFETY, OR ANY OTHER STATUTORY WARRANTY.  IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR
INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, EXEMPLARY, OR SPECIAL DAMAGES
INCURRED BY THE OTHER OR ANY AFFILIATE OR SUBSIDIARY ARISING OUT OF OR RELATED
TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY.

 

R.             diaDexus
agrees to defend, indemnify, and hold Lab, directors, officers, employees, and
agents wholly harmless from and against third-party claims, losses, lawsuits,
settlements, demands, causes, judgments, expenses, and cost (including
reasonable attorney fees) arising under or in connection with this Agreement
(collectively, referred to as “Claims”) in the event that such Claims are
caused by a) diaDexus’ breach of any of its warranties in this Agreement, b)
the failure of Products to function properly for the Permitted Use by Lab under
this Agreement, c) any gross negligence or willful misconduct of diaDexus, or
d) any other liability resulting from Lab’s use of the Products within the
Permitted Use under this Agreement. 
However, the foregoing rights to indemnity shall not apply to the extent
that such Claims result from Lab’s negligence or willful misconduct, including,
without limitation, the negligence of Lab’s employees, or from the modification
of any Product of diaDexus by Lab or a third party not within diaDexus’s control
or without diaDexus’ express written permission.  The obligation of diaDexus to defend,
indemnify and hold harmless shall also include, but is not limited to, any such
third-party claims, losses, damages, lawsuits, settlements, demands, causes,
judgments, expenses and costs (including reasonable attorney fees) against Lab
which relate in any manner to Lab’s alleged infringement of any property rights
of a third party in or to the Product or licenses under this Agreement.

 

BHL/diaDexus_070919

 

4

 

*
Confidential Treatment Requested by Celera Corporation*

 

Lab agrees to defend,
indemnify, and hold diaDexus and subsidiaries, directors, officers, employees,
and agents wholly harmless from and against any and all Claims that arise from (i) the
willful misconduct of Lab including, without limitation, modification of any
Product of diaDexus by Lab or a third party not within diaDexus’ control or
without diaDexus’ express written permission; Lab’s gross negligence or willful
misconduct, including, without limitation, the gross negligence of Lab’s
employees.  However, the foregoing rights
to indemnity shall not apply to the extent that such Claims result from
diaDexus’ negligence or willful misconduct including, without limitation, the
negligence of diaDexus’ employees, or from the modification of any Product of
Lab by diaDexus or a third party at diaDexus’ instruction.

 

For purposes of this
Paragraph R, the indemnified party shall give prompt written notice to the indemnifying
party of any suits, claims, or demands by third parties or the indemnified
party that may give rise to any Claim for which indemnification may be required
under this Paragraph R; provided, however, that failure to give
such notice shall not relieve the indemnifying party of its obligation to
provide indemnification hereunder except if and to the extent that such failure
materially affects the ability of the indemnifying party to defend the
applicable Claim.

 

The indemnifying party
shall be entitled to assume the defense and control of any such Claim at its
own cost and expense; provided, however, that the indemnified
party shall have the right to be represented by its own counsel at its own cost
in such matters.  In the event that the
indemnifying party declines to or fails to timely assume control of any such
Claim, the indemnified party shall be entitled to assume such control, conduct
the defense of, and settle such Claim, all at the sole cost and expense of the
indemnifying party.

 

Neither the indemnifying
party nor the indemnified party shall settle or dispose of any Claim in any
manner that would adversely affect the rights or interests of the other party
without the prior written consent of the other party, which shall not be
unreasonably withheld or delayed.  Each
party shall cooperate with the other party and its counsel in the course of the
defense of any Claim, such cooperation to include without limitation using
reasonable efforts to provide or make available documents, information, and witnesses

 

S.              diaDexus
shall, at its sole cost and expense, obtain and keep in force a policy of
comprehensive general liability insurance with bodily injury, death, and
property damage limits of One Million U.S. Dollars ($1,000,000) per occurrence
and Two Million U.S. Dollars ($2,000,000) in the aggregate and product
liability coverage insurance of One Million U.S. Dollars ($1,000,000) per
occurrence and One Million U.S. Dollars ($1,000,000) in aggregate.

 

T.             diaDexus
acknowledges that Lab has a proprietary interest in its legal and business name
and reputation.  Lab acknowledges that
diaDexus has a proprietary interest in its legal and business name and
reputation as well as the brand name and trademarks of its products.  Therefore, each party agrees that it shall
not use the other party’s name nor shall a party mention or describe this
Agreement or its relationship with the other party in any press release,
advertising, marketing, and promotional materials or other publications or
materials without first obtaining the prior written approval of the other
party.  Without limiting the foregoing,
diaDexus agrees not to use any name or mark of Lab or to quote the opinion of
any of Lab’s employees in any advertising or other publicity, including in
client lists or on diaDexus website, without obtaining the prior written
consent of Lab.

 

U.            Lab
shall label the Product as the PLAC® Test for Lp-PLA2, PLAC® Test,
or Lp-PLA2 on its test requisition order forms. 
If Lab wishes to market the diaDexus Product using the associated marks,
diaDexus hereby grants to Lab a non-exclusive, non-sublicensible license to use
its trademarks solely for the Permitted use.

 

V.             Audit
Rights; (a) Procedure.  Upon the
written request of diaDexus, and not more than once in each calendar year, Lab
will permit an independent auditing firm, e.g., Protiviti, selected by
diaDexus, and reasonably acceptable to Lab, at diaDexus’s expense, to have
access during normal business hours, and upon reasonable prior written notice,
to such of the records of Lab as may be reasonably necessary to verify the
accuracy of any financial information disclosed to diaDexus related to any
calendar quarter’s average net sales price within the preceding one (1) year
of that quarter’s final adjustment.  If
such firm concludes that additional payments were owed during such period, Lab
will pay the additional payments, with interest from the date originally due at
the prime rate, as published in The Wall Street Journal (Eastern U.S. Edition)
on the last business day preceding such date, within thirty (30) days after the
date such firm’s written report is delivered. 
If the amount of the underpayment is greater than five percent (5%) of
the total amount owed, then Lab will in addition reimburse diaDexus for its
reasonable costs related to such audit. (b) Confidentiality. The
independent auditing firm shall be required to maintain all information it
reviews in 

 

BHL/diaDexus_070919

 

5

 

*
Confidential Treatment Requested by Celera Corporation*

 

confidence, except
that it may report the summary balance of payment results of its audit to
diaDexus.  diaDexus will treat all
information subject to review under this Paragraph V in accordance with the
confidentiality provisions of Paragraph W, and will cause its firm to
enter into non-disclosure, non-use and Business Associate agreements reasonably
acceptable in form and substance to Lab, obligating such firm to retain all
such financial information in confidence and not otherwise use such information
pursuant to such confidentiality agreement. 
(c) Audit Disputes.  If Lab
in good faith disputes the conclusion of the firm under subsection (b) above
that Lab owes additional royalties or other payments, or any specific aspect of
the conclusion, then Lab will inform diaDexus by written notice within thirty
(30) days of receiving a copy of the audit containing such conclusion,
specifying in detail the reasons for Lab’s disputing such conclusion.  The parties will promptly thereafter meet and
negotiate in good faith a resolution to such dispute.  In the event that the parties are unable to
resolve such dispute within thirty (30) days after such notice, the matter will
be resolved pursuant to Paragraph X, and interest will be payable on any
additional payments determined to be due.

 

W.        The
parties have provided to each other prior to entering into this Agreement, and
in connection with this Agreement may in the future provide to each other,
confidential information, including but not limited to each party’s know-how,
invention disclosures, patent applications, proprietary materials and/or
technologies, economic information, business or research strategies, trade
secrets, and material embodiments thereof (“Confidential Information”).  The terms and conditions of this Agreement
shall be Confidential Information of the parties, and subject to the terms of
this Paragraph W.

 

The receiving party shall
maintain the Confidential Information of the disclosing party in confidence,
shall not disclose such Confidential Information to any third party, and shall
not use such Confidential Information for any purpose except as expressly
permitted under the terms and conditions of this Agreement.  Notwithstanding the previous sentence, the
receiving party may disclose the Confidential Information of the disclosing
party to its employees, agents, consultants, and professional, scientific,
medical, and legal advisors who have a need to know such Confidential
Information; provided that any such person to whom disclosure is made is
bound by obligations of non-disclosure and non-use no less restrictive then
those set forth herein.  The receiving
party shall take the same degree of care that such party uses to protect its
own confidential and proprietary information of a similar nature and
importance, but in no event shall such care be less than reasonable care.

 

The obligations of
non-disclosure and non-use under this Paragraph W will not apply as to
particular Confidential Information of a disclosing party to the extent that
such Confidential Information:  (a) is
at the time of receipt, or thereafter becomes, through no fault of the
receiving party, published or publicly known or available; (b) is known by
the receiving party at the time of receiving such information, as evidenced by
written records; (c) is hereafter furnished to the receiving party by a
third party without breach of a duty to the disclosing party; or (d) is
independently discovered or developed by the receiving party without use of,
application of, access to, or reference to Confidential Information of the
disclosing party as evidenced by written records. Both parties shall not,
directly or indirectly, (a) use the Confidential Information to guide or
aid a search and/or evaluation of publicly available information for purposes
of either showing the Confidential Information is in the public domain or to
recreate the knowledge or logic contained within the Confidential Information
from non-protected sources and/or (b) disassemble, reverse engineer or
otherwise use the Confidential Information as a guide or template to otherwise
recreate the logic or knowledge contained within the Confidential Information
and/or to directly or indirectly offer or use a product and/or service that
incorporates or uses the functionality of anything disclosed in the
Confidential Information or substantially equivalent to or substituting for,
any functionality disclosed by the other party in the Confidential Information
of such other party or for any other purpose.

 

Disclosure of Confidential
Information shall not be precluded if such disclosure (i) is in response
to a valid order of a court or other governmental body or (ii) is required
by law or regulation; provided, however, that the receiving party
shall first have given reasonable prior notice to the disclosing party and
shall have made a reasonable effort to obtain a protective order, or to
cooperate with the disclosing party’s efforts, as applicable, to obtain a
protective order limiting the extent of such disclosure and requiring that the
Confidential Information so disclosed be used only for the purposes for which
such order was issued or as required by such law or regulation.

 

The receiving party
agrees that its obligations under this Paragraph W are necessary and
reasonable to protect the disclosing party’s business interests and that the
unauthorized disclosure or use of Confidential Information of a disclosing
party will cause irreparable harm and significant injury, the degree of which
may be difficult to ascertain.  

 

BHL/diaDexus_070919

 

6

 

*
Confidential Treatment Requested by Celera Corporation*

 

The receiving party
further acknowledges and agrees that in the event of any actual or threatened
breach of this Paragraph W, the disclosing party may have no adequate
remedy at law and, accordingly, that the disclosing party will have the right
to seek an immediate injunction enjoining any breach or threatened breach of
this Paragraph W, as well as the right to pursue any and all other rights and
remedies available at law or in equity for such breach or threatened breach.

 

All obligations of
non-disclosure and non-use imposed pursuant to the terms and conditions of this
Paragraph W shall survive expiration or termination of this Agreement and
continue in full force and effect for a period of ten (10) years after the
effective date of such expiration or such termination.

 

X.            This Agreement is made in accordance with,
and this Agreement and any dispute arising out of, related to, or in connection
with this Agreement shall be governed and construed under, the laws of the
State of California, United States of
America, without giving effect to any choice of law principles that would
result in the application of the laws of any State other than the State of California.  Any
claim, dispute, or controversy arising out of or in connection with this
Agreement or the breach or alleged breach of this Agreement shall be submitted
for adjudication to the United States District Court, Northern District of California, or in the event that subject matter
jurisdiction does not exist in such Court, to the state court sitting within
the territory of the Northern District of California.  Each party hereby consents to personal
jurisdiction and venue in these courts.

 

Y.             The
relationship of the parties established by this Agreement is that of
independent contractors.  Nothing in this
Agreement shall be constructed to create any other relationship between the
parties.  Neither party shall have any
right, power, or authority to bind the other or assume, create, or incur any
expense, liability, or obligation, express or implied, on behalf of the other
party.  This Agreement is neither
expressly nor impliedly made for the benefit of any party other than those
executing it.

 

Z.             The
failure of a party to enforce any rights or provisions of the Agreement shall
not be construed to be a waiver of such rights or provisions, or a waiver by
such party to thereafter enforce such rights or provision or any other rights
or provisions hereunder.  No trade
customs, courses of dealing or courses of performance by the parties shall be
relevant to modify, supplement, or explain any term(s) used in this
Agreement.

 

	
  AA

  	
   

  	
  If any term, condition
  or provision of this Agreement is held to be unenforceable for any reason, it
  shall be interpreted to achieve the intent of the parties to this Agreement to the extent possible rather than
  voided. In any event, all other terms, conditions, and provisions of this
  Agreement shall be deemed valid and enforceable to the full extent.

  
	
   

  	
   

  	
   

  
	
  BB.

  	
   

  	
  Each party shall carry
  out its activities pursuant to this Agreement in compliance with all
  applicable federal, state, and local laws, rules, regulations, and
  guidelines.

  
	
   

  	
   

  	
   

  
	
  CC.

  	
   

  	
  Upon the execution of
  this Agreement, diaDexus shall simultaneously execute a Business Associate
  Agreement with Lab in a form substantially similar to the one attached hereto
  as Exhibit A.

  
	
   

  	
   

  	
   

  
	
  DD.

  	
   

  	
  This Agreement may be
  executed in counterparts, each of which shall be deemed an original and all
  of which together shall constitute one instrument.

  

 

BHL/diaDexus_070919

 

7

 

*
Confidential Treatment Requested by Celera Corporation*

 

	
  EE.

  	
   

  	
  To the extent that
  there is any conflict or inconsistency between this Agreement and any
  purchase order, the attached Product Addendum, or any other document
  pertaining to the supply of Product, the terms of this Agreement shall govern
  unless specifically acknowledged and agreed to in writing by each of the
  parties.

  

 

 

	
  Berkeley
  HeartLab, Inc.

  	
   

  	
  diaDexus, Inc.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:
  

  	
        /s/
  Frank Ruderman

  	
   

  	
  By:
  

  	
        /s/
  Patrick Plewman

  
	
   

  	
   

  	
   

  	
   

  
	
  Print
  Name: Frank Ruderman

  	
  Patrick
  Plewman

  
	
   

  	
   

  
	
  Title: President

  	
  Title:
  President & CEO

  
	
   

  	
   

  	
   

  
	
  Date: November 9,
  2007

  	
  Date:
  11/16/07

  
						

 

BHL/diaDexus_070919

 

8

 

*
Confidential Treatment Requested by Celera Corporation*

 

diaDexus -  Berkeley
HeartLab, Inc.

PRODUCT ADDENDUM

 

	
  Catalog #

  	
   

  	
  Description

  	
   

  	
  Lab Price

  
	
  90106

  	
   

  	
  GEN3 PLAC® Test Kit for
  Lp-PLA2 96-well microplate ELISA kit

  	
   

  	
  [***]

  
	
  90104

  	
   

  	
  GEN3 PLAC® Test
  Controls 2 controls, 1 vial each, 3 mL each

  	
   

  	
  [***]

  

 

Lab will issue a “snapshot”
sales report to diaDexus on or before the 10th calendar day of each
month for the prior month’s expected utilization of Product (the “Snapshot
Report”), delineating between patient reportable results and CRO results.  diaDexus will invoice Lab, using the Lab
Price schedule above, on the 10th calendar day of each month based
on Lab’s Snapshot Report of total Patient and total CRO results from the
preceding month.  Lab will provide a
report by the 20th calendar day of each month for the immediate
prior month’s actual utilization of Product (the “Final Report”).  Any difference between the Snapshot Report
and the Final Report will be accounted for in the subsequent month’s
invoice.  For clarification and as an
example only: on or before the 10th calendar day of October, Lab
would issue a Snapshot Report for September’s expected utilization and diaDexus
would immediately invoice.  By October 20th,
Lab would issue a Final Report for September’s actual utilization and any
difference between the Snapshot and Final Reports would be accounted for in the
November 10th invoice.

 

	
  Net Sales Reconciliation*

  
	
   

  
	
  [***]

  

 

BHL/diaDexus_070919

 

9

 

*
Confidential Treatment Requested by Celera Corporation*

 

TERMS
AND CONDITIONS AS SET FORTH IN THE MASTER SUPPLY AGREEMENT

SHALL
APPLY TO THIS PRODUCT ADDENDUM

 

	
  Pricing
  Effective

  	
   

  	
  Expires

  
	
  Date:
  January 1, 2007

  	
   

  	
  Date:
  September 30, 2008

  
	
   

  	
   

  	
   

  
	
  Berkeley
  HeartLab, Inc.

  	
   

  	
  diaDexus, Inc.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
    /s/  Frank
  Ruderman

  	
   

  	
  By:

  	
     /s/
  Patrick Plewman

  
					

 

	
  Print
  Name:

  	
  Frank
  Ruderman

  	
  Patrick
  Plewman

  
	
   

  	
   

  
	
  Title:

  	
  President

  	
  Title:
  President & CEO

  
	
   

  	
   

  
	
  Date:

  	
  November 9,
  2007

  	
  Date:

  	
   

  	
  11/16/07

  	
   

  

 

Term: [* * *]

 

BHL/diaDexus_070919

 

10

 

* Confidential Treatment
Requested by Celera Corporation*

 

EXHIBIT A

 

diaDexus-  Berkeley
Heart Lab, Inc.

Business Associate Agreement

 

This Business Associate
Agreement (“Agreement”) is entered into this 1st day of November 2007 (the
“Effective Date”) by and between Berkeley HeartLab, Inc., a California
corporation (“BHL”), and diaDexus, Inc., a Delaware corporation (“Contractor”).

 

RECITALS

 

A.            Pursuant to HIPAA, BHL, as a Covered Entity, as defined
in 45 C.F.R. §160.103, is required to enter into this Agreement to obtain
satisfactory assurances that Contractor, a Business Associate, will
appropriately safeguard all Protected Health Information disclosed, created or
received by Contractor on behalf of, BHL.

 

B.            BHL desires to engage Contractor to perform certain
functions for, or on behalf of, BHL involving the disclosure of PHI by BHL to
Contractor, or the creation or use of PHI by Contractor on behalf of BHL, and
Contractor desires to perform such functions.

 

C.            This contract shall be deemed an amendment to the parties’
Master Supply Agreement dated November 1, 2007 (“Underlying Agreement”).

 

In
consideration of the mutual promises below and the exchange of information
pursuant to this Agreement and in order to comply with all legal requirements
for the protection of this information, the parties therefore agree as follows:

 

Article I. Definitions of Terms

 

1.01         Business Associate shall have the meaning given to
such term in 45 C.F.R. §160.103.

 

1.02         C.F.R. shall mean the Code of Federal
Regulations.  All references to the
C.F.R. are to their then current version.

 

1.03         Designated Record Set shall have the meaning given to
such term in 45 C.F.R. §164.501.

 

1.04                           ePHI shall mean
electronically created, received, maintained or transmitted PHI.

 

1.05         HIPAA shall mean the Health Information Portability
and Accountability Act of 1996, as amended from time to time.

 

1.06         Privacy Laws shall mean HIPAA,
the HIPAA regulations and any other applicable state or federal laws or
regulations affecting or regulating the privacy and/or security of health
information (65 Fed. Reg. 82462-82829 (December 28, 2000 and as amended on
August 14, 2002 in 67 Fed Reg. 53,182-53273 (Part 160 and 164).)).

 

1.07         Protected Health Information (“PHI”) shall have the
meaning given to such term in 45 C.F.R. §164.501 and other applicable state
Privacy Laws.

 

1.08         “Required by Law” shall have the meaning given to
such phrase in 45 C.F.R. §164.501.

 

1.09         Security Rule shall have the meaning given such
term in 45 C.F.R. § 164.302-164.318.

 

BHL/diaDexus_070919

 

11

 

* Confidential Treatment Requested by Celera Corporation*

 

Article II.               Obligations
of Contractor

 

2.01         HIPAA Obligations.  Contractor acknowledges that federal
regulations relating to the confidentiality of PHI requires Covered Entities
and Business Associates to comply with HIPAA. 
HIPAA requires BHL to ensure that Business Associates who receive
confidential information in the course of providing services on behalf of BHL
comply with certain HIPAA obligations regarding the confidentiality of
PHI.  Accordingly, Contractor shall only
use and/or disclose PHI in a manner consistent with this Agreement, the
Underlying Agreement, the Privacy Rule, the Security Rule or as Required
by Law and only in connection with providing services hereunder.

 

2.02         Permitted Uses and Disclosures.  In connection with the services provided by
Contractor to BHL, Contractor may not use or disclose PHI received or created
pursuant to this Agreement as set forth in this Section 2.  Contractor shall maintain appropriate
safeguards to ensure that PHI is not used or disclosed other than as provided
by this Agreement or as required by Law.  Except
as may be limited by this Agreement, Contractor may use or disclose PHI it obtains or creates in its
capacity as Contractor for the proper management and administration of the
Contractor, to carry out Contractor’s legal responsibilities
under the Underlying Agreement
and this Agreement; provided that any
disclosures are Required by Law.
Contractor shall, if it makes a disclosure as permitted hereunder, (i) provide
training to members of Contractor’s workforce regarding the confidentiality
requirements in the Privacy Laws, the Security Rule and this Agreement;
and (ii) obtain reasonable assurances from the person to whom the information is disclosed that it will remain confidential and used or further disclosed only for the
purpose for which it was disclosed to such person and in accordance with the
Privacy Laws, and such person will notify Contractor of any instances of which it is aware
in which the confidentiality of such PHI has been breached.  Further, Contractor shall ensure that any use or disclosure of PHI are
subject to the principle of “minimum necessary use and disclosure,” i.e., only the PHI that is the
minimum necessary to accomplish the intended purpose of the use, disclosure, or
request may be disclosed.  Notwithstanding anything to the
contrary in this Agreement, Contractor may use PHI to report violations of law
to appropriate federal and state authorities, consistent with 45 C.F.R.
§164.502(j)(1), but only to the extent such reports are required by Law and
provided that (a) a copy of each such report is provided to BHL and (b) a
complete and accurate summary of any oral disclosure is provided to BHL.

 

Contractor shall require the
recipient of any PHI to agree to the same restrictions and conditions that
apply to Contractor under this Agreement as to the PHI, unless BHL agrees to
the contrary in writing with respect to a specific release of information.

 

2.03         Withdrawal of Authorization.  If the use or disclosure of PHI in this
Agreement is based upon an individual’s specific authorization for the use of
his or her PHI, and such individual revokes such authorization in writing, or
the effective date of such authorization has expired, or the authorization is
found to be defective in any manner that renders it invalid, BHL shall notify
Contractor of such revocation, expiration or defect in the authorization and
thereafter, Contractor shall cease the use and disclosure of any such
individual’s PHI except to the extent it has relied on such use or disclosure,
or where an exception under the Privacy Laws expressly applies.

 

2.04         ePHI
Security.  Contractor shall do all
the following:

(a)   Implement
administrative, physical and technical safeguards that reasonably and
appropriately protect the confidentiality, security, integrity and availability
of ePHI that Contractor creates,
receives, maintains or transmits on behalf of BHL, which in any event shall be
no less than the HIPAA-related implementation recommendations of the NIST/URAC/WEDI Health Care Security Workgroup (see www.wedi.org; keyword search “NIST” or “URAC”)
;

 

(b)   Ensure
that any agent, including a subcontractor, to whom Contractor provides ePHI agrees in writing to implement
reasonable and appropriate safeguards to protect ePHI; and

 

BHL/diaDexus_070919

 

12

 

* Confidential Treatment Requested by Celera Corporation*

 

(c)   Upon
request, make available to BHL Contractor’s documented information security
program, including the most recent ePHI risk analysis, policies, procedures,
security incidents and responses, and evidence of training.

 

2.05         Access to PHI by Individuals.  Contractor shall cooperate with BHL to
fulfill all requests by individuals for access to the individual’s PHI in a
Designated Record Set that are approved by BHL. 
Contractor shall cooperate with BHL in all respects necessary for BHL to
comply with applicable Privacy Laws. 
Because California law requires that copies of requested records be
forwarded to patients within fifteen (15) days of their request, Contractor
agrees to forward any copies requested by BHL for this purpose within 5
business days.  If Contractor receives a
request from an individual for access to PHI, Contractor promptly shall forward
such request to BHL and await BHL’s instructions with respect to denial or
approval of such request.  BHL shall be
solely responsible for determining the scope of PHI and Designated Record Set
with respect to each request by an individual for access to PHI.  Upon instruction from BHL, Contractor shall
deny such individual’s request or fulfill such individual’s request by
providing such individual’s PHI to such individual.  BHL shall reimburse Contractor a portion of
the fee charged by BHL to the individual that is proportional to the amount of
PHI produced by Contractor in relation to the amount of PHI produced by BHL,
less reasonable BHL administrative expenses.

 

2.06         Amendment of PHI. 
As directed and in accordance with the time frames reasonably specified
by BHL, Contractor shall incorporate all amendments or addenda to PHI received
from BHL, pursuant to 45 C.F.R. §164.526 and similar applicable Privacy
Laws.  Within ten (10) business days
following Contractor’s amendment of PHI as directed by BHL, Contractor shall
provide written notice to BHL confirming that Contractor has made the
amendments or addenda to PHI as directed by BHL and containing any other
information as may be necessary for BHL to provide adequate notice to the
individual in accordance with 45 C.F.R. §164.526 and similar applicable Privacy
Laws.

 

2.07.        Disclosure Accounting. In the event that Contractor
makes any disclosures of PHI that are subject to the accounting requirements of
45 C.F.R. §164.528, Contractor promptly shall report such disclosures to BHL.
The notice by Contractor to BHL of the disclosure shall include the name of the
individual, the recipient, and the reason for disclosure, and the date of the
disclosure.  Contractor shall maintain a
record of each such disclosure, including the date of the disclosure, the name
and, if available, the address of the recipient of the PHI, a brief description
of the PHI disclosed and a brief description of the purpose of the
disclosure.  Contractor shall maintain
this record for a period of six (6) years and make available to BHL upon
request in an electronic format so that BHL may meet its disclosure accounting
obligations under 45 C.F.R. §164.528.

 

2.08         Reporting and Mitigating Unauthorized Uses and
Disclosures of PHI.  Promptly
following its notice of the same, Contractor shall report to BHL any uses,
disclosures or risks of disclosure of PHI not authorized by this Agreement of
which it becomes aware and, with respect to ePHI, any
security incident, including any attempted or successful unauthorized access,
use, disclosure, modification, or destruction of ePHI or interference with information system operations all
as required by applicable Privacy Laws and applicable state identity theft laws
(e.g., Cal. Civ. Code §1798.82). 
Contractor agrees to mitigate, to the extent practicable, the
deleterious effects of any use or disclosure of PHI not authorized by this Agreement.

 

2.09         Ownership of Information.  As between Contractor and BHL, all PHI and ePHI shall be deemed owned by BHL unless otherwise agreed in
writing by BHL.  During the term of this
Agreement, Contractor and any authorized subcontractors shall have the right to
use the PHI and ePHI solely for the purposes of
this Agreement.  Contractor and its
agents shall not have the right to de-identify the PHI and/or ePHI unless agreed in writing by BHL.

 

2.10         Internal Practices, Books, and Records.  Contractor shall make available its internal
practices, books, and records relating to the use and disclosure of PHI
received from, created, or received by Contractor on behalf of BHL to the U.S.
Department of Heath and Human Services or his designee for the purpose of
determining BHL’s compliance with 45 C.F.R. pt. 160 and 164, subparts A and E
and amendments thereto.

 

BHL/diaDexus_070919

 

13

 

* Confidential Treatment Requested by Celera Corporation*

 

2.11         BHL’s Obligations.

 

(a)   BHL shall notify Contractor of any limitation(s) in
its notice of privacy practices of BHL in accordance with 45 C.F.R. § 164.520,
to the extent that such limitation may affect Contractor’s use or disclosure of
PHI.

 

(b) 
BHL shall notify Contractor of any changes in, or revocation of, permission by
individual to use or disclose PHI, to the extent that such changes may affect
Contractor’s use or disclosure of PHI.

 

(c) 
BHL shall notify Contractor of any restriction to the use or disclosure of PHI
that BHL has agreed to in accordance with 45 C.F.R. § 164.522, to the extent
that such restriction may affect Contractor’s use or disclosure of such PHI.

 

2.12         Permitted Requests from BHL.  BHL shall not request Contractor to use or
disclose PHI in any manner that would not be permissible under the Privacy Rule if
done by BHL.

 

Article III.              Term
and Termination

 

3.01         Term.  This Agreement shall commence the Effective
Date and end when one party notifies the other party of its intent to terminate
pursuant to Section 3.02.

 

3.02         Termination. 
Either party to this Agreement may terminate the Agreement upon
provision of thirty (30) days’ prior written notice.

 

3.03         Effects of Termination; Disposal of PHI and/or ePHI. Upon termination of this Agreement, Contractor
shall return to BHL or destroy all PHI and/or ePHI
that Contractor obtained or maintained pursuant to this Agreement on behalf of
BHL, including the PHI and/or ePHI in the
possession of any of Contractor’s agents or affiliates.  If the parties determine that returning or
destroying the PHI is infeasible, Contractor shall provide to BHL notification
of the specific conditions that make return or destruction infeasible.  Contractor shall extend the protections
provided under this Agreement to such PHI and/or ePHI,
and limit further use or disclosure of such PHI and/or ePHI
to those purposes that make the return or destruction of the PHI and/or ePHI infeasible. 
Contractor shall require that its agents, affiliates, subsidiaries and
subcontractors agree to the extension of all protections, limitations and
restrictions required of Contractor hereunder to the extent such agents,
affiliates, subsidiaries or subcontractors are in possession of such PHI and/or
ePHI.  This Section 3.03 shall
survive the termination of this Agreement.

 

Article IV.              Miscellaneous

 

4.01         Notices.  Any
notice required to be given pursuant to the terms and provisions of this
Agreement shall be in writing and may be either personally delivered, sent by
commercial; overnight delivery service or sent by registered or certified mail in
the United States Postal Service, Return Receipt Requested, postage prepaid,
addressed to each party at the addresses which follow or to such other
addresses as the parties may hereinafter designate in writing:

 

	
   

  	
  BHL:

  	
  839 Mitten Road

  	
   

  	
   

  
	
   

  	
   

  	
  Burlingame,
  CA 94010

  	
   

  	
   

  
	
   

  	
   

  	
  Attn:

  	
  General
  Counsel

  	
   

  
						

 

BHL/diaDexus_070919

 

14

 

* Confidential Treatment Requested by Celera Corporation*

 

	
  Contractor:

  	
   

  	
  diaDexus, Inc.

  	
   

  	
   

  
	
   

  	
   

  	
  343 Oyster Point Boulevard

  	
   

  	
   

  
	
   

  	
   

  	
  South San Francisco, CA
  94080-1913

  	
   

  	
   

  
	
   

  	
   

  	
  Attn:

  	
  Patrick Plewman

  	
   

  
	
   

  	
   

  	
   

  	
  Chief Executive Officer

  	
   

  
						

 

Any such notice shall be
deemed to have been given, if mailed as provided herein, as of the date
received.

 

4.02         Amendments. 
This Agreement may, from time to time, be modified or amended in writing
and such written modifications are signed by both parties to this Agreement.

 

4.03         Counterparts. 
This Agreement may be executed in counterparts, any of which is
considered to be an original agreement.

 

4.04         Assignment/Subcontracting.  This Agreement shall inure to the benefit of
and be binding upon the parties hereto and their respective legal
representatives, successors and assigns. 
Neither party may assign the rights or obligations under this Agreement
without the express written consent of the other party; provided, however, that
either party may assign this Agreement without such consent to any permitted
assignee of such party’s rights and obligations under the Underlying Agreement.

 

4.05         Construction. 
This Agreement shall be construed as broadly as necessary to implement
and comply with the HIPAA regulations. 
The parties agree that any ambiguity in this Agreement shall be resolved
in favor of a meaning that complies and is consistent with the HIPAA
regulations.

 

IN
WITNESS WHEREOF, the parties hereto have duly executed this agreement to be
effective as of the date of the Underlying Agreement.

 

	
  BHL

  	
   

  	
  CONTRACTOR

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Frank
  Ruderman

  	
   

  	
  Patrick
  Plewman

  
	
   

  	
   

  	
   

  
	
  Title:
  President

  	
   

  	
  Title:
  Chief Executive Officer

  
	
   

  	
   

  	
   

  
	
  Date:
  November 9, 2007

  	
   

  	
  Date:

  	
  11/16/07

  

 

BHL/diaDexus_070919

 

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00141-of-00352.parquet"}]]